EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tilki Derya, van den Bergh Roderick C N, Briers Erik, Van den Broeck Thomas, Brunckhorst Oliver, Darraugh Julie, Eberli Daniel, De Meerleer Gert, De Santis Maria, Farolfi Andrea, Gandaglia Giorgio, Gillessen Silke, Grivas Nikolaos, Henry Ann M, Lardas Michael, J L H van Leenders Geert, Liew Matthew, Linares Espinos Estefania, Oldenburg Jan, van Oort Inge M, Oprea-Lager Daniela E, Ploussard Guillaume, Roberts Matthew J, Rouvière Olivier, Schoots Ivo G, Schouten Natasha, Smith Emma J, Stranne Johan, Wiegel Thomas, Willemse Peter-Paul M, Cornford Philip
Аннотация
METHODS: The panel performed a literature review of new data, covering the time frame between 2020 and 2023. The guidelines were updated and a strength rating for each recommendation was added on the basis of a systematic review of the evidence.
KEY FINDINGS AND LIMITATIONS: Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. New treatment options, such as androgen receptor-targeted agents (ARTAs), ARTA + chemotherapy combinations, PARP inhibitors and their combinations, and prostate-specific membrane antigen-based therapy have become available for men with metastatic PCa.
CONCLUSIONS AND CLINICAL IMPLICATIONS: Evidence for relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These guidelines reflect the multidisciplinary nature of PCa management. The full version is available online (http://uroweb.org/guideline/ prostate-cancer/).
PATIENT SUMMARY: This article summarises the 2024 guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are based on evidence and guide doctors in discussing treatment decisions with their patients. The guidelines are updated every year.